TY - JOUR T1 - Validation of CXCL10 as a biomarker of respiratory tract infections detectable by lateral flow immunoassay JF - ERJ Open Research JO - erjor DO - 10.1183/23120541.LSC-2022.66 VL - 8 IS - suppl 8 SP - 66 AU - Dayna Mikkelsen AU - Jennifer A. Aguiar AU - Julia Danieli AU - Prakriti Chhabra AU - Benjamin J-M Tremblay AU - Manjot S. Hunjan AU - Victoria Kirkness AU - Jodi Gilchrist AU - David Bulir AU - Marek Smieja AU - Sojin Lee AU - Nader Shaikh AU - Hamza Mbareche AU - Samira Mubareka AU - Kha Tram AU - Andrew C. Doxey AU - Jeremy Hirota Y1 - 2022/03/10 UR - http://openres.ersjournals.com/content/8/suppl_8/66.abstract N2 - Introduction: Biomarkers of respiratory tract infections historically focused on the etiological cause of infection, although much of the morbidity and mortality is driven by the host-pathological response.Aim: Determine host biomarkers indicative of viral respiratory tract infections that are amenable to lateral flow immunoassay (LFIA) testing.Methods: Datamining was performed on in-house and publicly available datasets from respiratory syncytial virus (RSV), rhinovirus, influenza A and SARS-CoV-2 infected patient nasopharyngeal swab samples and compared to healthy controls. CXCL10, CXCL11 and TNFSF10 gene expression levels were assessed and a correlation analysis was performed in relation to infection severity and time-course. Lastly, the signature was validated at the protein level in saliva as a prerequisite for development of a host-response LFIA.Results: CXCL10 and CXCL11 upregulation was positively correlated with RSV when compared to control (p= 0.016, p= 0.006). No significant association was found with influenza A or rhinovirus for all three genes. CXCL10/CXCL11/TNFSF10 upregulation was positively correlated with SARS-CoV-2 infection when compared to control (p < 0.001). CXCL10 expression correlated with COVID-19 severity and had the lowest variance over infection time-course. CXCL10 was not detected at the protein level in healthy saliva but was elevated in saliva from COVID-19 patients. A CXCL10 LFIA was developed with a sensitivity of 2 ng/ml in a buffer and artificial saliva.Conclusion: The findings validate the potential utility of examining host immune responses during viral respiratory tract infections by exploring CXCL10 as a biomarker detectable by LFIA.FootnotesCite this article as ERJ Open Research 2022; 8: Suppl. 8, 66.This article was presented at the 2022 ERS Lung Science Conference, in session “Poster Session 2”.This is an ERS Lung Science Conference abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only). ER -